# A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

> **NCT05325346** · PHASE1 · COMPLETED · sponsor: **Veralox Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Heparin-induced Thrombocytopenia

## Interventions

- **DRUG:** VLX-1005
- **DRUG:** Argatroban

## Key facts

- **NCT ID:** NCT05325346
- **Lead sponsor:** Veralox Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325346, "A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05325346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*